Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells

Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells

Minimal change disease (MCD) is a common cause of nephrotic syndrome. Treatment with steroids is usually effective, but frequent relapses are therapeutic challenges. The anti-CD20 antibody rituximab has shown promising results for treatment of steroid-sensitive nephrotic syndrome. Since predictive b...

Full description

Bibliographic Details
Main Authors: Maximilian Webendörfer, Linda Reinhard, Rolf A. K. Stahl, Thorsten Wiech, Hans-Willi Mittrücker, Sigrid Harendza, Elion Hoxha
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Immunology
Subjects:
minimal change disease
rituximab
CD20+ T cells
B cell depletion therapy
nephrotic syndrome
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.586012/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.586012/full

Similar Items